TABLE 1.
Patients characteristics
| A. HCC Patients | |
|---|---|
| Parameter | n = 148 |
| Female/Male | 27/121 |
| Age (years) | 70.5 (64.6–75.8) |
| Types of hepatitis | |
| Hepatitis B (%) | 32 (21.6) |
| Hepatitis C (%) | 49 (33.1) |
| Non B, non C (%) | 66 (44.6) |
| Hepatitis B, C (%) | 1 (.7) |
| Patients with primary HCC/recurrent HCC | 95/53 |
| Maximum tumour diameter (cm) | 3.1 (2.0–5.5) |
| Number of tumours | |
| Single (%) | 98 (66.2) |
| More than 2 (%) | 50 (33.8) |
| White blood cell count (×103/μl) | 5.25 (4.40–6.37) |
| Hemoglobin content (g/dl) | 13.5 (12.4–14.8) |
| Platelet count (×104/μl) | 15.8 (12.4–20.4) |
| C‐reactive protein CRP (mg/dl) | .07 (.03‐.20) |
| Albumin (g/dl) | 4.0 (3.7–4.3) |
| Aspartate aminotransferase AST (U/L) | 31.0 (24.0–52.7) |
| Alanine aminotransferase ALT (U/L) | 29.0 (19.0–44.0) |
| Gamma‐glutamyl transferase GGT (U/L) | 48.0 (29.0–104.7) |
| Total bilirubin (mg/dl) | .7 (.6–1.0) |
| Creatinine (mg/dl) | .81 (.68–.92) |
| Triglyceride (mg/dl) | 99 (71.5–134.0) |
| Total cholesterol (mg/dl) | 172 (150–194) |
| Fasting blood glucose (mg/dl) | 103.5 (93.7–124.0) |
| HbA1c (NGSP) (%) | 5.8 (5.5–6.6) |
| Prothrombin time‐ Int'l normalized ratio PT‐INR | .96 (.93–1.01) |
| ICGR15 (%) | 12.0 (9.0–21.0) |
| Alpha‐fetoprotein AFP (ng/ml) | 7.5 (3.9–44.9) |
| AFP‐L3 (%) | 2.1 (.5–13.7) |
| Des‐gamma‐carboxy prothrombin DCP (mAu/ml) | 37 (17.0–403.8) |
| Background liver | |
| Fibrosis stage 0 / 1 / 2 / 3 / 4 | 17/22/28/41/40 |
| Activity grade 0 / 1 / 2 | 15/108/25 |
| Tumour differentiation | |
| Well (%) | 24 (16.2) |
| Well to moderate (%) | 39 (26.4) |
| Moderate (%) | 57 (38.5) |
| Moderate to poor (%) | 21 (14.2) |
| Poor (%) | 7 (4.7) |
| Microvascular invasion | (+)/(–) 36/112 |
| Female/Male | 3 / 30 |
| Age (years) | 71 (66–79) |
| Histology | |
| Squamous Cell Carcinoma/Adenocarcinoma | 32/1 |
| Cancer cell differentiation | |
| Well | 4 |
| Moderate | 12 |
| Poor | 4 |
| Undifferentiated | 5 |
| Tumour position | |
| Cervical | 3 |
| Upper thoracic | 7 |
| Middle thoracic | 15 |
| Lower thoracic | 8 |
| Lymph node metastasis (+/‐) | 18/15 |
| Recurrence | |
| Intra | 3 |
| Extra | 12 |
| White blood cell count (×103/μl) | 6.0 (4.9–8.0) |
| Hemoglobin content (g/dl) | 13.8 (12.6–14.7) |
| Platelet count (×104/μl) | 23.4 (20.6–29.6) |
| CRP (mg/dl) | .10 (.05–.65) |
| Albumin (g/dl) | 4.1 (3.9–4.3) |
| CYFRA (ng/ml) | 2.3 (1.25–2.85) |
| SCC (ng/ml) | 1.8 (1.1–2.5) |
| Anti‐p53 (U/ml) | .4 (.4–1.0) |
| Fibrinogen (mg/dl) | 420 (379–528) |
| Brain natriuretic peptide BNP (mg/ml) | 27.6 (18.6–44.3) |
| Tumour stage | |
| T I / II / III/ IV | 7/3/17/6 |
Abbreviation: HCC, human hepatocellular carcinoma.